Table 3.
Means of IGF-1 and IGF-1/IGFBP-3 at three time intervals and the odds ratios for colorectal adenomas by the levels of the serum hormone measurements at each time point and by their patterns of change over the period of ten years.
| MEAN (SD) | OR (95% CI) | |||||
|---|---|---|---|---|---|---|
| IGF-1 (ng/ml) | IGF-1/IGFBP-3 (molar ratio) | IGF-1 (ng/ml) | IGF-1/IGFBP-3 (molar ratio) | |||
| controls | cases | controls | cases | |||
| A. Time points: | ||||||
| 1. 1992-1994a | 126 (42) | 118 (44) | 0.14 (0.04) | 0.13 (0.04) | 0.76 (0.32,1.66) | 0.74 (0.33,1.56) |
| 2. 1997-1999a | 118 (41) | 118 (42) | 0.14 (0.04) | 0.13 (0.03) | 1.13 (0.50, 2.44) | 1.04 (0.50,2.06) |
| 3. 2002-2004a | 120 (50) | 123 (52) | 0.13 (0.04) | 0.14 (0.04) | 1.24 (0.64, 2.40) | 1.44 (0.73,2.86) |
| B. Pattern of change in IGF-1 or IGF-1/IGFBP-3 in the 10-year follow-up period: | ||||||
| Ever Increase versus No Increaseb | 3.81 (1.35,11.30) | 2.83 (1.00, 8.22) | ||||
a
ORs are adjusted for age (baseline), center, race/ethnicity, gender, and the following concurrent measurements: BMI and IGFBP-3; OR is scaled to the difference between 25% to 75% percentile in all subjects at baseline.
b
ORs are adjusted for age (baseline), center, race/ethnicity, gender, and BMI (baseline), IGF-1 (baseline); additionally, ORs for IGF-1 are adjusted for baseline IGFBP-3.